7-Year watch: tracking safety of groundbreaking ALS drug
NCT ID NCT07259980
Summary
This study aims to monitor the long-term safety of tofersen (Qalsody), a prescription drug for a specific genetic form of ALS. Researchers will follow about 125 people with SOD1-ALS for at least 7 years, collecting health data from their regular clinic visits. The main goal is to track serious health problems and understand why some people might stop treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mass General Hospital -MGH
Boston, Massachusetts, 02114, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.